Federal Register / Vol. 89, No. 232 / Tuesday, December 3, 2024 / Notices 95793 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Avg. burden 

per response 

(in hrs.) 

Total burden 

(in hrs.) 

Researcher ........................................ Research Data Center proposal ...... 110 1 3 330 

Total ........................................... ........................................................... 330 ........................ ........................ ........................

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–28322 Filed 12–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0100] 

Draft CDC’s Recommendations for HIV 

Screening in Clinical Settings 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention in the 

Department of Health and Human 

Services announces the opening of a 

docket to obtain comment on the draft 

Recommendations for HIV Screening in 

Clinical Settings, that update portions of 

CDC’s ‘‘Revised Recommendations for 

HIV Testing of Adults, Adolescents, and 

Pregnant Women in Health-Care 

Settings,’’ published in 2006. 

DATES: Written comments must be 

received on or before January 2, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0100 by either of the methods listed 

below. Do not submit comments by 

email. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: National Center for HIV, Viral 

Hepatitis, STD, and TB Prevention, 

CDC, 1600 Clifton Road NE, Mailstop 

U.S. 8–6, Atlanta, GA 30329–4027. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to https://regulations.gov, including any 

personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Cecily Campbell, National Center for 

HIV, Viral Hepatitis, STD, and TB 

Prevention, CDC, 1600 Clifton Road NE, 

Mailstop U.S. 8–6, Atlanta, GA 30329– 

4027, Email: nchhstppolicy@cdc.gov. 

Office phone: 404–639–0485. 

SUPPLEMENTARY INFORMATION: CDC is 

requesting public comment on the draft 

‘‘Recommendations for HIV Screening 

in Clinical Settings,’’ which is available 

on regulations.gov in Docket CDC– 

2024–0100. These recommendations 

modify the ages for HIV screening 

including eliminating an upper age 

limit, encourage providers to use 

clinical decision support tools such as 

automated HIV test laboratory orders to 

implement HIV screening, provide 

considerations for healthcare 

populations on which to conduct HIV 

screening, recommend anyone who 

requests a test should be tested, and 

emphasize the use of a general consent 

process as used for other routine tests. 

CDC describes the methods and 

supporting evidence in the 

recommendations. The 

recommendations’ objectives are to 

diagnose and link patients with 

undiagnosed infection to clinical care; 

relink persons with previously 

diagnosed HIV to clinical care; diagnose 

HIV infection earlier; and reduce HIV 

transmission in the United States. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. In addition, CDC invites comments 

specifically on the following questions 

proposed in this document: 

• Does the evidence presented 

support the proposed recommendations 

for HIV screening in clinical settings, 

including the benefits and harms of HIV 

screening? If not, please state the reason 

why and, if available, provide 

additional evidence for consideration. 

• Are CDC’s proposed 

recommendations for HIV screening in 

clinical settings clearly written? If not, 

what changes do you propose to make 

it clearer? 

• If implemented as currently drafted, 

do you believe these recommendations 

would improve HIV screening in 

clinical settings, improve diagnoses and 

linking patients with undiagnosed 

infection to clinical care; relinking 

persons with previously diagnosed HIV 

to clinical care; diagnosing HIV 

infection earlier; and reducing HIV 

transmission in the United States? If 

not, please provide an explanation and 

supporting data or evidence. 

• How should CDC disseminate the 

final recommendations to effectively 

reach end users such as healthcare 

providers in clinical settings? 

• After the recommendations are 

finalized, CDC is planning to publish an 

implementation guide for healthcare 

providers to supplement the updated 

recommendations. What should the 

implementation guide include? 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 

comment or supporting materials that 

you consider confidential or 

inappropriate for public disclosure. If 

you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be on 

public display. CDC will review all 

submissions and may choose to redact, 

or withhold, submissions containing 

private or proprietary information such 

as Social Security numbers, medical 

information, inappropriate language, or 

duplicate/near duplicate examples of a 

mass-mail campaign. Do not submit 

comments by email. CDC does not 

accept comment by email. 

After the comments received on the 

draft are considered and addressed, the 

final recommendations will be 

published on CDC’s website at https:// 

www.cdc.gov/hiv/guidelines/ 

testing.html. The final recommendations 

will also be posted to docket CDC– 

2024–0100 at www.regulations.gov. 

Background 

Human immunodeficiency virus 

(HIV) is a virus that attacks the body’s 

immune system. The only way a person 

can know their HIV status is by getting 

tested (CDC, 2024a). While there is no 


lotter on DSK11XQN23PROD with NOTICES1
95794 Federal Register / Vol. 89, No. 232 / Tuesday, December 3, 2024 / Notices 

cure, people with HIV who get on and 

stay on effective HIV treatment can live 

long, healthy lives and protect their 

partners (CDC, 2024a). 

While the number of persons living 

with HIV in the United States has 

slightly increased from an estimated 1.1 

million people at the end of 2006 to 1.2 

million people in 2022, the estimated 

HIV incidence has decreased from 

48,600 in 2006 to 31,800 in 2022 

(Campsmith, Rhodes, Hall, & Green, 

2008; CDC, 2024b; Prejean et al., 2011). 

There are now better HIV assays for 

more accurate diagnosis, improved 

antiretroviral treatment, pre-exposure 

prophylaxis, post-exposure prophylaxis, 

and self-testing, which taken together 

improve the prevention, diagnosis, and 

treatment of HIV infections. 

In 2006, the CDC published ‘‘Revised 

Recommendations for HIV Testing of 

Adults, Adolescents, and Pregnant 

Women in Health-Care Settings,’’ 

(hereafter referred to as 2006 HIV 

Testing Recommendations). These 

guidelines transformed the HIV testing 

paradigm in the United States by 

recommending routine, voluntary HIV 

screening among all adults and 

adolescents between 13–64 years of age 

unless prevalence of undiagnosed HIV 

infection in their patients has been 

documented to be less than 0.1%. In 

addition, it was recommended that 

repeat screening of persons not likely to 

be at high risk for HIV should be 

performed based on clinical judgment. 

The 2006 HIV Testing 

Recommendations aimed to normalize 

HIV screening. To update the evidence, 

CDC conducted an in-depth systematic 

review and analysis of other data 

sources using rigorous methods for 

guidelines development. CDC obtained 

input from the public prior to starting 

the update process and from internal 

and external experts at different points 

in the process. CDC seeks to engage a 

diverse range of perspectives to inform 

the development of the 

recommendations, improve their 

credibility, and increase the 

transparency of the process. 

CDC invites written comments by the 

public (any interested persons or 

organizations) on the draft HIV 

screening guideline. These 

recommendations will also undergo 

peer review. 

Noah Aleshire, 

Chief Regulatory Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2024–28294 Filed 12–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–25–1365; Docket No. CDC–2024– 

0099] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Performance 

Monitoring of CDC’s Core State Injury 

Prevention Program (SIPP). The goal of 

Core SIPP is to strengthen the awardee’s 

injury prevention programs and policies 

and demonstrate impact in the 

reduction of injury-related morbidity 

and mortality. 

DATES: CDC must receive written 

comments on or before February 3, 

2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0099 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Performance Monitoring of CDC’s 

Core State Injury Prevention Program 

(SIPP) (OMB Control No. 0920–1365, 

Exp. 7/31/2025)—Revision—National 

Center for Injury Prevention and Control 

(NCIPC), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

This is a Revision request for the 

currently approved Performance 

Monitoring of CDC’s Core State Injury 

Prevention Program (SIPP) (OMB 

Control No. 0920–1369, Exp. Date 7/31/ 

2025). Approval is requested for an 

additional three years to continue 

collecting information from awardees 

funded under the Core SIPP cooperative 

agreement. Data collected up until this 


lotter on DSK11XQN23PROD with NOTICES1